PMCB
PharmaCyte Biotech Inc
$
0.876
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.9699
Open
0.830
VWAP
0.90
Vol
65.85K
Mkt Cap
6.01M
Low
0.813
Amount
59.26K
EV/EBITDA(TTM)
--
Total Shares
8.45M
EV
-11.06M
EV/OCF(TTM)
--
P/S(TTM)
--
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
--
--
-0.090
+50%
Estimates Revision
Stock Price
Go Down
-17.14%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for PharmaCyte Biotech Inc (PMCB.O) is -2.51, compared to its 5-year average forward P/E of -9.45. For a more detailed relative valuation and DCF analysis to assess PharmaCyte Biotech Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.45
Current PE
-2.51
Overvalued PE
6.04
Undervalued PE
-24.94
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q3
0.00
Total Revenue
FY2025Q3
YoY :
-48.62%
-960.25K
Operating Profit
FY2025Q3
YoY :
+391.55%
-3.05M
Net Income after Tax
FY2025Q3
YoY :
-32.31%
-0.44
EPS - Diluted
FY2025Q3
YoY :
+187.91%
-509.89K
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PMCB News & Events
News
-.-
2024-05-21SeekingAlphaPharmaCyte Biotech announces $7 million strategic investment in MYMD
-.-
2022-10-07globenewswirePharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
Sign Up For More News
People Also Watch
FAQ
What is PharmaCyte Biotech Inc (PMCB) stock price today?
The current price of PMCB is 0.8759 USD — it has increased 5.54 % in the last trading day.
What is PharmaCyte Biotech Inc (PMCB)'s business?
What is the price predicton of PMCB Stock?
What is PharmaCyte Biotech Inc (PMCB)'s revenue for the last quarter?
What is PharmaCyte Biotech Inc (PMCB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for PharmaCyte Biotech Inc (PMCB)'s fundamentals?
How many employees does PharmaCyte Biotech Inc (PMCB). have?